Citation: B. Rodda et al., Statistics and the drug development process, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 3-14
Citation: B. Pikounis, One-factor comparative studies, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 17-40
Citation: H. Ahn et Rl. Kodell, Analysis of animal carcinogenicity data, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 43-73
Authors:
Hoffman, WP
Heathman, MA
Chou, JZ
Allen, DL
Citation: Wp. Hoffman et al., Analysis of toxicokinetic and pharmacokinetic data from animal studies, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 75-106
Citation: H. Nguyen et D. Amaratunga, Analysis of pharmacokinetic data, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 109-133
Citation: J. Bock, Graphical presentation of single patient results, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 135-151
Citation: B. Pikounis et al., Graphical insight and data analysis for the 2,2,2 crossover design, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 153-188
Citation: A. Benner et al., Design and analysis of Phase I trials in clinical oncology, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 189-216
Citation: Wp. Wang, Patient compliance and its impact on steady state pharmacokinetics, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 217-236
Authors:
Ette, EI
Lockwood, P
Miller, R
Mandema, J
Citation: Ei. Ette et al., Analysis of analgesic trials, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 237-266
Citation: J. Bock, Power and sample size calculations, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 269-297
Citation: M. Jahn, Comparing two treatments in a large Phase III clinical trial, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 299-320
Citation: M. Olson, Analysis of variance: A comparison between SAS and S-PLUS, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 321-347
Citation: V. Berger et A. Ivanova, Permutation tests for Phase III clinical trials, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 349-374
Citation: Wp. Wang et A. Krause, Sample size reestimation, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 375-396
Citation: K. O'Rourke et al., Meta-analysis of clinical trials, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 397-424
Citation: Jr. Cook et al., Analysis of health economic data, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 427-454
Citation: J. Eisele et al., Evaluation of the decimal reduction time of a sterilization process in pharmaceutical production, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 457-474
Citation: H. Yang et D. Carlin, Acceptance sampling plans by attributes, APPLIED STATISTICS IN THE PHARMACEUTICAL INDUSTRY: WITH CASE STUDIES USINGS-PLUS, 2001, pp. 475-502